PPARδ agonism for the treatment of obesity and associated disorders: Challenges and opportunities

PPAR Research

Volumn , Issue , 2008, Pages

  Perreault, Mylène ^a   Erbe, David V ^a   Tobin, James F ^a  

^a PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; 3 CHLORO 4 [3 (7 PROPYL 3 TRIFLUOROMETHYLBENZISOXAZOL 6 YLOXY)PROPYLTHIO]PHENYLACETIC ACID; [2 METHYL 4 [4 METHYL 2 (4 TRIFLUOROMETHYLPHENYL) 5 THIAZOLYLMETHYLTHIO]PHENOXY]ACETIC ACID; ADIPONECTIN; CARNITINE PALMITOYLTRANSFERASE; DIURETIC AGENT; FATTY ACID; FENOFIBRATE; FIBRIC ACID DERIVATIVE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; KETONE BODY; LIPOPROTEIN LIPASE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; N OLEOYLETHANOLAMINE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA AGONIST; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ANTAGONIST; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR DELTA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PIOGLITAZONE; PIRINIXIC ACID; PLACEBO; RETINOID X RECEPTOR; ROSIGLITAZONE; SIBUTRAMINE; TETRAHYDROLIPSTATIN; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

ADIPOCYTE; CARDIOVASCULAR EFFECT; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; COMORBIDITY; CONGESTIVE HEART FAILURE; DIABETES MELLITUS; DIABETIC OBESITY; DIET; DNA BINDING; DRUG MECHANISM; DRUG TARGETING; DYSLIPIDEMIA; ENERGY EXPENDITURE; EPIDEMIC; EXERCISE; FATTY ACID OXIDATION; GENE EXPRESSION; GLUCOSE METABOLISM; HEART INFARCTION; HUMAN; LIPID METABOLISM; LIPID STORAGE; METABOLIC DISORDER; MITOCHONDRIAL RESPIRATION; NONHUMAN; OBESITY; PHYSICAL ACTIVITY; PLACEBO EFFECT; PREVALENCE; REVIEW; TREATMENT FAILURE; TRIACYLGLYCEROL BLOOD LEVEL; VAGUS NERVE; WEIGHT REDUCTION;

EID: 55949136076     PISSN: 16874757     EISSN: 16874765     Source Type: Journal    
DOI: 10.1155/2008/125387     Document Type: Review

References (104)

1. Hossain P., Kawar B., El Nahas M., Obesity and diabetes in the developing world-a growing challenge The New England Journal of Medicine 2007 356 3 213 215
2. Abu-Abid S., Szold A., Klausner J., Obesity and cancer Journal of Medicine 2002 33 1-4 73 86
3. Garfinkel L., Overweight and cancer Annals of Internal Medicine 1985 103 6, part 2 1034 1036
4. Gillum R. F., The association of body fat distribution with hypertension, hypertensive heart disease, coronary heart disease, diabetes and cardiovascular risk factors in men and women aged 18-79 years Journal of Chronic Diseases 1987 40 5 421 428
5. Pender J. R., Pories W. J., Epidemiology of obesity in the United States Gastroenterology Clinics of North America 2005 34 1 1 7
6. Petry N. M., Barry D., Pietrzak R. H., Wagner J. A., Overweight and obesity are associated with psychiatric disorders: results from the national epidemiologic survey on alcohol and related conditions Psychosomatic Medicine 2008 70 3 288 297
7. Fontana L., Eagon J. C., Trujillo M. E., Scherer P. E., Klein S., Visceral fat adipokine secretion is associated with systemic inflammation in obese humans Diabetes 2007 56 4 1010 1013
8. Lyon C. J., Law R. E., Hsueh W. A., Minireview: adiposity, inflammation, and atherogenesis Endocrinology 2003 144 6 2195 2200
9. Thörne A., Lönnqvist F., Apelman J., Hellers G., Arner P., A pilot study of long-term effects of a novel obesity treatment: omentectomy in connection with adjustable gastric banding International Journal of Obesity 2002 26 2 193 199
10. Klein S., Fontana L., Young L., Absence of an effect of liposuction on insulin action and risk factors for coronary heart disease The New England Journal of Medicine 2004 350 25 2549 2557
11. Rucker D., Padwal R., Li S. K., Curioni C., Lau D. C. W., Long term pharmacotherapy for obesity and overweight: updated meta-analysis British Medical Journal 2007 335 7631 1194 1199
12. Miller C. A., Rosen C. J., Summary Minutes of the Endocrinologic and Metabolic Drugs Advisory Committee meeting on June 13, 2007. Food and Drug Administration, Center for Drug Evaluation and Research, 2007, http://www.fda.gov/ohrms/dockets/ac/07/minutes/2007-4306m1-final.pdf
13. Buse J. B., Klonoff D. C., Nielsen L. L., Metabolic effects of two years of exenatide treatment on diabetes, obesity, and hepatic biomarkers in patients with type 2 diabetes: an interim analysis of data from the open-label, uncontrolled extension of three double-blind, placebo-controlled trials Clinical Therapeutics 2007 29 1 139 153
14. Chia C. W., Egan J. M., Special features: incretin-based therapies in type 2 diabetes mellitus The Journal of Clinical Endocrinology & Metabolism 2008 93 10 3703 3716
15. FDA, Information for Healthcare Professionals. 2008, http://www.fda.gov/ cder/drug/infopage/exenatide/default.htm
16. Wang Y.-X., Lee C.-H., Tiep S., Peroxisome-proliferator-activated receptor δ activates fat metabolism to prevent obesity Cell 2003 113 2 159 170
17. Mangelsdorf D. J., Thummel C., Beato M., The nuclear receptor superfamily: the second decade Cell 1995 83 6 835 839
18. Willson T. M., Brown P. J., Sternbach D. D., Henke B. R., The PPARs: from orphan receptors to drug discovery Journal of Medicinal Chemistry 2000 43 4 527 550
19. Heinzel T., Lavinsky R. M., Mullen T.-M., A complex containing N-CoR, mSln3 and histone deacetylase mediates transcriptional repression Nature 1997 387 6628 43 48
20. Cavailles V., Dauvois S., L'Horset F., Nuclear factor RIP140 modulates transcriptional activation by the estrogen receptor The EMBO Journal 1995 14 15 3741 3751
21. Chen J. D., Umesono K., Evans R. M., SMRT isoforms mediate repression and anti-repression of nuclear receptor heterodimers Proceedings of the National Academy of Sciences of the United States of America 1996 93 15 7567 7571
22. Onate S. A., Tsai S. Y., Tsai M.-J., O'Malley B. W., Sequence and characterization of a coactivator for the steroid hormone receptor superfamily Science 1995 270 5240 1354 1357
23. Gelman L., Zhou G., Fajas L., Raspé E., Fruchart J.-C., Auwerx J., p300 interacts with the N- and C-terminal part of PPAR γ 2 in a ligand-independent and -dependent manner, respectively The Journal of Biological Chemistry 1999 274 12 7681 7688
24. Heinlein C. A., Ting H.-J., Yeh S., Chang C., Identification of ARA70 as a ligand-enhanced coactivator for the peroxisome proliferator-activated receptor γ The Journal of Biological Chemistry 1999 274 23 16147 16152
25. Wilding J., Thiazolidinediones, insulin resistance and obesity: finding a balance International Journal of Clinical Practice 2006 60 10 1272 1280
26. de Souza C. J., Eckhardt M., Gagen K., Effects of pioglitazone on adipose tissue remodeling within the setting of obesity and insulin resistance Diabetes 2001 50 8 1863 1871
27. Spiegelman B. M., PPAR- γ: adipogenic regulator and thiazolidinedione receptor Diabetes 1998 47 4 507 514
28. Yamauchi T., Kamon J., Waki H., The mechanisms by which both heterozygous peroxisome proliferator-activated receptor γ (PPAR γ) deficiency and PPAR γ agonist improve insulin resistance The Journal of Biological Chemistry 2001 276 44 41245 41254
29. Kelly I. E., Han T. S., Walsh K., Lean M. E. J., Effects of a thiazolidinedione compound on body fat and fat distribution of patients with type 2 diabetes Diabetes Care 1999 22 2 288 293
30. Miyazaki Y., Mahankali A., Matsuda M., Effect of pioglitazone on abdominal fat distribution and insulin sensitivity in type 2 diabetic patients The Journal of Clinical Endocrinology & Metabolism 2002 87 6 2784 2791
31. Hevener A. L., Olefsky J. M., Reichart D., Macrophage PPAR γ is required for normal skeletal muscle and hepatic insulin sensitivity and full antidiabetic effects of thiazolidinediones Journal of Clinical Investigation 2007 117 6 1658 1669
32. Hammarstedt A., Sopasakis V. R., Gogg S., Jansson P.-A., Smith U., Improved insulin sensitivity and adipose tissue dysregulation after short-term treatment with pioglitazone in non-diabetic, insulin-resistant subjects Diabetologia 2005 48 1 96 104
33. Jiang G., Dallas-Yang Q., Li Z., Potentiation of insulin signaling in tissues of Zucker obese rats after acute and long-term treatment with PPAR γ agonists Diabetes 2002 51 8 2412 2419
34. Kubota N., Terauchi Y., Kubota T., Pioglitazone ameliorates insulin resistance and diabetes by both adiponectin-dependent and -independent pathways The Journal of Biological Chemistry 2006 281 13 8748 8755
35. Fruchart J.-C., Novel peroxisome proliferator activated receptor- α agonists American Journal of Cardiology 2007 100 11, supplement 1 S41 S46
36. Elangbam C. S., Tyler R. D., Lightfoot R. M., Peroxisome proliferator-activated receptors in atherosclerosis and inflammation-an update Toxicologic Pathology 2001 29 2 224 231
37. Francis G. A., Fayard E., Picard F., Auwerx J., Nuclear receptors and the control of metabolism Annual Review of Physiology 2003 65 261 311
38. Fu J., Gaetani S., Oveisi F., Oleylethanolamide regulates feeding and body weight through activation of the nuclear receptor PPAR- α Nature 2003 425 6953 90 93
39. Carmona M. C., Louche K., Nibbelink M., Fenofibrate prevents Rosiglitazone-induced body weight gain in ob/ob mice International Journal of Obesity 2005 29 7 864 871
40. Rodríguez de Fonseca F., Navarro M., Gómez R., An anorexic lipid mediator regulated by feeding Nature 2001 414 6860 209 212
41. Inagaki T., Dutchak P., Zhao G., Endocrine regulation of the fasting response by PPAR α -mediated induction of fibroblast growth factor 21 Cell Metabolism 2007 5 6 415 425
42. Badman M. K., Pissios P., Kennedy A. R., Koukos G., Flier J. S., Maratos-Flier E., Hepatic fibroblast growth factor 21 is regulated by PPAR α and is a key mediator of hepatic lipid metabolism in ketotic states Cell Metabolism 2007 5 6 426 437
43. Kharitonenkov A., Wroblewski V. J., Koester A., The metabolic state of diabetic monkeys is regulated by fibroblast growth factor-21 Endocrinology 2007 148 2 774 781
44. Scharrer E., Control of food intake by fatty acid oxidation and ketogenesis Nutrition 1999 15 9 704 714
45. Sun M., Martin R. J., Edwards G. L., ICV β -hydroxybutyrate: effects on food intake, body composition, and body weight in rats Physiology and Behavior 1997 61 3 433 436
46. Barish G. D., Narkar V. A., Evans R. M., PPAR δ: a dagger in the heart of the metabolic syndrome Journal of Clinical Investigation 2006 116 3 590 597
47. Arsenijevic D., De Bilbao F., Plamondon J., Increased infarct size and lack of hyperphagic response after focal cerebral ischemia in peroxisome proliferator-activated receptor β -deficient mice Journal of Cerebral Blood Flow and Metabolism 2006 26 3 433 445
48. Tanaka T., Yamamoto J., Iwasaki S., Activation of peroxisome proliferator-activated receptor δ induces fatty acid β -oxidation in skeletal muscle and attenuates metabolic syndrome Proceedings of the National Academy of Sciences of the United States of America 2003 100 26 15924 15929
49. Fürnsinn C., Willson T. M., Brunmair B., Peroxisome proliferator-activated receptor- δ, a regulator of oxidative capacity, fuel switching and cholesterol transport Diabetologia 2007 50 1 8 17
50. Sprecher D. L., Massien C., Pearce G., Triglyceride: high-density lipoprotein cholesterol effects in healthy subjects administered a peroxisome proliferator activated receptor δ agonist Arteriosclerosis, Thrombosis, and Vascular Biology 2007 27 2 359 365
51. Kannisto K., Chibalin A., Glinghammar B., Zierath J. R., Hamsten A., Ehrenborg E., Differential expression of peroxisomal proliferator activated receptors α and δ in skeletal muscle in response to changes in diet and exercise International Journal of Molecular Medicine 2006 17 1 45 52
52. Luquet S., Lopez-Soriano J., Holst D., Peroxisome proliferator-activated receptor δ controls muscle development and oxidative capability The FASEB Journal 2003 17 15 2299 2301
53. Mahoney D. J., Parise G., Melov S., Safdar A., Tarnopolsky M. A., Analysis of global mRNA expression in human skeletal muscle during recovery from endurance exercise The FASEB Journal 2005 19 11 1498 1500
54. Watt M. J., Southgate R. J., Holmes A. G., Febbraio M. A., Suppression of plasma free fatty acids upregulates peroxisome proliferator-activated receptor (PPAR) α and δ and PPAR coactivator 1 α in human skeletal muscle, but not lipid regulatory genes Journal of Molecular Endocrinology 2004 33 2 533 544
55. Wang Y.-X., Zhang C.-L., Yu R. T., Regulation of muscle fiber type and running endurance by PPAR δ PLoS Biology 2004 2 10 e294
56. Lee C.-H., Olson P., Hevener A., PPAR δ regulates glucose metabolism and insulin sensitivity Proceedings of the National Academy of Sciences of the United States of America 2006 103 9 3444 3449
57. Kang K., Reilly S. M., Karabacak V., Adipocyte-derived Th2 cytokines and myeloid PPAR δ regulate macrophage polarization and insulin sensitivity Cell Metabolism 2008 7 6 485 495
58. Odegaard J. I., Ricardo-Gonzalez R. R., Eagle A. R., Alternative M2 activation of Kupffer cells by PPAR δ ameliorates obesity-induced insulin resistance Cell Metabolism 2008 7 6 496 507
59. Tugwood J. D., Holden P. R., James N. H., Prince R. A., Roberts R. A., A peroxisome proliferator-activated receptor-alpha (PPAR α) cDNA cloned from guinea-pig liver encodes a protein wit h similar properties to the mouse PPAR α: implications for species differences in responses to peroxisome proliferators Archives of Toxicology 1998 72 3 169 177
60. Graham T. L., Mookherjee C., Suckling K. E., Palmer C. N. A., Patel L., The PPAR δ agonist GW0742X reduces atherosclerosis in LDLR-/-mice Atherosclerosis 2005 181 1 29 37
61. Li A. C., Binder C. J., Gutierrez A., Differential inhibition of macrophage foam-cell formation and atherosclerosis in mice by PPAR α, β / δ, and γ Journal of Clinical Investigation 2004 114 11 1564 1576
62. Takata Y., Liu J., Yin F., PPAR δ -mediated antiinflammatory mechanisms inhibit angiotensin II-accelerated atherosclerosis Proceedings of the National Academy of Sciences of the United States of America 2008 105 11 4277 4282
63. Oliver W. R. Jr., Shenk J. L., Snaith M. R., A selective peroxisome proliferator-activated receptor δ agonist promotes reverse cholesterol transport Proceedings of the National Academy of Sciences of the United States of America 2001 98 9 5306 5311
64. Vu-Dac N., Chopin-Delannoy S., Gervois P., The nuclear receptors peroxisome proliferator-activated receptor α and Rev-erb α mediate the species-specific regulation of apolipoprotein A-I expression by fibrates The Journal of Biological Chemistry 1998 273 40 25713 25720
65. Staels B., Auwerx J., Regulation of apo A-I gene expression by fibrates Atherosclerosis 1998 137 supplement 1 S19 S23
66. Rudolph J., Libing C., Majumdar D., Indanylacetic acid derivatives carrying 4-thiazolyl-phenoxy tail groups, a new class of potent PPAR α / γ / δ pan agonists: synthesis, structure-activity relationship, and in vivo efficacy Journal of Medicinal Chemistry 2007 50 5 984 1000
67. Berger J., Leibowitz M. D., Doebber T. W., Novel peroxisome proliferator-activated receptor (PPAR) γ and PPAR δ ligands produce distinct biological effects The Journal of Biological Chemistry 1999 274 10 6718 6725
68. Willson T. M., Cobb J. E., Cowan D. J., The structure-activity relationship between peroxisome proliferator-activated receptor γ agonism and the antihyperglycemic activity of thiazolidinediones Journal of Medicinal Chemistry 1996 39 3 665 668
69. Perreault M., PPAR pan agonists: novel approaches to treating type 2 diabetes and metabolic syndrome Obesity 2006 14 supplement A62
70. Perreault M., PPAR pan agonists induce body weight loss in DIO mice Obesity 2006 14 supplement A62
71. Cheol S. C., Savage D. B., Abu-Elheiga L., Continuous fat oxidation in acetyl-CoA carboxylase 2 knockout mice increases total energy expenditure, reduces fat mass, and improves insulin sensitivity Proceedings of the National Academy of Sciences of the United States of America 2007 104 42 16480 16485
72. Abu-Elheiga L., Matzuk M. M., Abo-Hashema K. A. H., Wakil S. J., Continuous fatty acid oxidation and reduced fat storage in mice lacking acetyl-COA carboxylase 2 Science 2001 291 5513 2613 2616
73. Finck B. N., Bernal-Mizrachi C., Han D. H., A potential link between muscle peroxisome proliferator-activated receptor- α signaling and obesity-related diabetes Cell Metabolism 2005 1 2 133 144
74. Djouadi F., Aubey F., Schlemmer D., Bastin J., Peroxisome proliferator activated receptor δ (PPAR δ) agonist but not PPAR α corrects carnitine palmitoyl transferase 2 deficiency in human muscle cells The Journal of Clinical Endocrinology & Metabolism 2005 90 3 1791 1797
75. Pruimboom-Brees I., Haghpassand M., Royer L., A critical role for peroxisomal proliferator-activated receptor- α nuclear receptors in the development of cardiomyocyte degeneration and necrosis American Journal of Pathology 2006 169 3 750 760
76. Finck B. N., Han X., Courtois M., A critical role for PPAR α -mediated lipotoxicity in the pathogenesis of diabetic cardiomyopathy: modulation by dietary fat content Proceedings of the National Academy of Sciences of the United States of America 2003 100 3 1226 1231
77. Burkart E. M., Sambandam N., Han X., Nuclear receptors PPAR β / δ and PPAR α direct distinct metabolic regulatory programs in the mouse heart Journal of Clinical Investigation 2007 117 12 3930 3939
78. Pesant M., Sueur S., Dutartre P., Peroxisome proliferator-activated receptor δ (PPAR δ) activation protects H9c2 cardiomyoblasts from oxidative stress-induced apoptosis Cardiovascular Research 2006 69 2 440 449
79. Koves T. R., Ussher J. R., Noland R. C., Mitochondrial overload and incomplete fatty acid oxidation contribute to skeletal muscle insulin resistance Cell Metabolism 2008 7 1 45 56
80. Yki-Järvinen H., Thiazolidinediones The New England Journal of Medicine 2004 351 11 1106 1118
81. Nissen S. E., Wolski K., Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes The New England Journal of Medicine 2007 356 24 2457 2471
82. GlaxoSmithKline, Advisory Committee Briefing Document, Cardiovascular Safety of Rosiglitazone, Endocrinologic and Metabolic Drugs Advisory Committee, Drug Safety and Risk Management Advisory Committee, Meeting on July 30, 2007
83. Diamond G. A., Bax L., Kaul S., Uncertain effects of rosiglitazone on the risk for myocardial infarction and cardiovascular death Annals of Internal Medicine 2007 147 8 578 581
84. McAfee A. T., Koro C., Landon J., Ziyadeh N., Walker A. M., Coronary heart disease outcomes in patients receiving antidiabetic agents Pharmacoepidemiology and Drug Safety 2007 16 7 711 725
85. Lincoff A. M., Wolski K., Nicholls S. J., Nissen S. E., Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials Journal of the American Medical Association 2007 298 10 1180 1188
86. Goldberg R. B., Kendall D. M., Deeg M. A., A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidemia Diabetes Care 2005 28 7 1547 1554
87. Qin S., Liu T., Kamanna V. S., Kashyap M. L., Pioglitazone stimulates apolipoprotein A-I production without affecting HDL removal in HepG2 cells: involvement of PPAR- α Arteriosclerosis, Thrombosis, and Vascular Biology 2007 27 11 2428 2434
88. Sakamoto J., Kimura H., Moriyama S., Activation of human peroxisome proliferator-activated receptor (PPAR) subtypes by pioglitazone Biochemical and Biophysical Research Communications 2000 278 3 704 711
89. Home P. D., Pocock S. J., Beck-Nielsen H., Rosiglitazone evaluated for cardiovascular outcomes-an interim analysis The New England Journal of Medicine 2007 357 1 28 38
90. Drazen J. M., Morrissey S., Curfman G. D., Rosiglitazone-continued uncertainty about safety The New England Journal of Medicine 2007 357 1 63 64
91. Nathan D. M., Rosiglitazone and cardiotoxicity-weighing the evidence The New England Journal of Medicine 2007 357 1 64 66
92. Psaty B. M., Furberg C. D., The record on rosiglitazone and the risk of myocardial infarction The New England Journal of Medicine 2007 357 1 67 69
93. FDA, Guidance for Industry: Diabetes Mellitus: Developing Drugs and Therapeutic Biologics for Treatment and Prevention. Draft Guidance, FDA, 2008
94. Aoki T., Current status of carcinogenicity assessment of peroxisome proliferator-activated receptor agonists by the US FDA and a mode-of-action approach to the carcinogenic potential Journal of Toxicologic Pathology 2008 20 4 197 202
95. Schwartz A. V., Sellmeyer D. E., Thiazolidinediones: new evidence of bone loss The Journal of Clinical Endocrinology & Metabolism 2007 92 4 1232 1234
96. Kahn S. E., Zinman B., Lachin J. M., Rosiglitazone-associated fractures in type 2 diabetes: an analysis from A Diabetes Outcome Progression Trial (ADOPT) Diabetes Care 2008 31 5 845 851
97. Meier C., Kraenzlin M. E., Bodmer M., Jick S. S., Jick H., Meier C. R., Use of thiazolidinediones and fracture risk Archives of Internal Medicine 2008 168 8 820 825
98. Lazarenko O. P., Rzonca S. O., Hogue W. R., Swain F. L., Suva L. J., Lecka-Czernik B., Rosiglitazone induces decreases in bone mass and strength that are reminiscent of aged bone Endocrinology 2007 148 6 2669 2680
99. Ali A. A., Weinstein R. S., Stewart S. A., Parfitt A. M., Manolagas S. C., Jilka R. L., Rosiglitazone causes bone loss in mice by suppressing osteoblast differentiation and bone formation Endocrinology 2005 146 3 1226 1235
100. Wan Y., Chong L.-W., Evans R. M., PPAR- γ regulates osteoclastogenesis in mice Nature Medicine 2007 13 12 1496 1503
101. Giaginis C., Tsantili-Kakoulidou A., Theocharis S., Peroxisome proliferator-activated receptors (PPARs) in the control of bone metabolism Fundamental and Clinical Pharmacology 2007 21 3 231 244
102. Jackson S. M., Demer L. L., Peroxisome proliferator-activated receptor activators modulate the osteoblastic maturation of MC3T3-E1 preosteoblasts FEBS Letters 2000 471 1 119 124
103. Mano H., Kimura C., Fujisawa Y., Cloning and function of rabbit peroxisome proliferator-activated receptor δ / β in mature osteoclasts The Journal of Biological Chemistry 2000 275 11 8126 8132
104. Maurin A. C., Chavassieux P. M., Meunier P. J., Expression of PPAR γ and β / δ in human primary osteoblastic cells: influence of polyunsaturated fatty acids Calcified Tissue International 2005 76 5 385 392